Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s43440-021-00225-3 http://scihub22266oqcxt.onion/10.1007/s43440-021-00225-3 33666864!7933916!33666864     free     free     free Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pharmacol+Rep 2021 ; 73 (3): 728-735 Nephropedia Template TP {{tp|p=33666864|t=2021. Perspectives on glucocorticoid treatment for COVID-19: a systematic review |pdf=|usr=}}{{33666864}} gab.com Text Perspectives on glucocorticoid treatment for COVID-19: a systematic review JO: Pharmacol Rep http://www.kidney.de/pget.php?&tw=1&pmid=33666864 #FOAvip Coronavirus disease 2019 (COVID-19) is a viral pneumonia that can lead to acute respiratory distress syndrome (ARDS). Until the commercialization of a vaccine, pharmacological treatment still represents an important strategy to fight against the ongoing pandemic. Glucocorticoids (GC) were widely used in the past coronavirus pandemics and have been used against the coronavirus 2 severe acute respiratory syndrome (SARS-CoV-2). This article aimed to review the studies that described the treatment with GC in COVID-19 patients. Randomized or nonrandomized clinical trials and retrospective or prospective-controlled longitudinal studies were screened for this systematic review. Studies in English, Portuguese, and Spanish published since 2019, with participants of any clinical status, geographic location, age, and sex were included. The most significant interest was related to the length of stay, radiological profile changes, viremia, and mortality. The research was done electronically on the Pubmed database using the following terms: "corticosteroids", "glucocorticoids", "dexamethasone", "methylprednisolone", "COVID-19", "SARS- CoV-2", "ADRS". We identified 6332 publications, and at the end, 14 retrospective observational studies that met all the inclusion criteria were selected. These studies included only patients infected with SARS-CoV-2 confirmed by RT-PCR, involving 2,713 participants. The results showed great heterogeneity in their designs and results, which precludes a reliable conclusion on the use of GCs in the treatment of COVID-19. Twit Text FOAVip Perspectives on glucocorticoid treatment for COVID-19: a systematic review ????Pharmacol Rep http://www.kidney.de/pget.php?&tw=1&pmid=33666864 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33666864 #FOAvip English Wikipedia <ref>{{Cite pmid|33666864}}</ref> Perspectives on glucocorticoid treatment for COVID-19: a systematic review #MMPMID33666864 Cordeiro LP; Linhares EONN; Nogueira FGO; Moreira-Silva D; Medeiros-Lima DJM Pharmacol Rep 2021[Jun]; 73 (3): 728-735 PMID33666864show ga Coronavirus disease 2019 (COVID-19) is a viral pneumonia that can lead to acute respiratory distress syndrome (ARDS). Until the commercialization of a vaccine, pharmacological treatment still represents an important strategy to fight against the ongoing pandemic. Glucocorticoids (GC) were widely used in the past coronavirus pandemics and have been used against the coronavirus 2 severe acute respiratory syndrome (SARS-CoV-2). This article aimed to review the studies that described the treatment with GC in COVID-19 patients. Randomized or nonrandomized clinical trials and retrospective or prospective-controlled longitudinal studies were screened for this systematic review. Studies in English, Portuguese, and Spanish published since 2019, with participants of any clinical status, geographic location, age, and sex were included. The most significant interest was related to the length of stay, radiological profile changes, viremia, and mortality. The research was done electronically on the Pubmed database using the following terms: "corticosteroids", "glucocorticoids", "dexamethasone", "methylprednisolone", "COVID-19", "SARS- CoV-2", "ADRS". We identified 6332 publications, and at the end, 14 retrospective observational studies that met all the inclusion criteria were selected. These studies included only patients infected with SARS-CoV-2 confirmed by RT-PCR, involving 2,713 participants. The results showed great heterogeneity in their designs and results, which precludes a reliable conclusion on the use of GCs in the treatment of COVID-19. |*COVID-19 Drug Treatment[MESH] |COVID-19/virology[MESH] |Glucocorticoids/*therapeutic use[MESH] |Humans[MESH] |Pneumonia, Viral/drug therapy/virology[MESH] |Prospective Studies[MESH] |Randomized Controlled Trials as Topic[MESH] |Retrospective Studies[MESH]Perspectives on glucocorticoid treatment for COVID-19: a systematic re(epmc).pdf DeepDyve Pubget Overpricing